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ABSTRACT
Background Human de novo single-nucleotide
variation (SNV) rate is estimated to range between
0.82–1.70×10−8 mutations per base per generation.
However, contribution of early postzygotic mutations
to the overall human de novo SNV rate is unknown.
Methods We performed deep whole-genome
sequencing (more than 30-fold coverage per individual)
of the whole-blood-derived DNA samples of a healthy
monozygotic twin pair and their parents. We examined
the genotypes of each individual simultaneously for each
of the SNVs and discovered de novo SNVs regarding the
timing of mutagenesis. Putative de novo SNVs were
validated using Sanger-based capillary sequencing.
Results We conservatively characterised 23 de novo
SNVs shared by the twin pair, 8 de novo SNVs specific
to twin I and 1 de novo SNV specific to twin II. Based
on the number of de novo SNVs validated by Sanger
sequencing and the number of callable bases of each
twin, we calculated the overall de novo SNV rate of
1.31×10−8 and 1.01×10−8 for twin I and twin II,
respectively. Of these, rates of the early postzygotic de
novo SNVs were estimated to be 0.34×10−8 for twin
I and 0.04×10−8 for twin II.
Conclusions Early postzygotic mutations constitute a
substantial proportion of de novo mutations in humans.
Therefore, genome mosaicism resulting from early mitotic
events during embryogenesis is common and could
substantially contribute to the development of diseases.
INTRODUCTION
Mutations provide the means of genetic diversity
on which natural selection operates. Characterising
the patterns and rate of de novo mutations is
crucial to the understanding of mutational pro-
cesses that may lead to evolution and human
disease.1 Recent studies based on the direct obser-
vation of de novo single-nucleotide variation (SNV)
in parent–offspring trios revealed a rate that spans
a wide range (0.82–1.70×10−8 mutations per base
per generation).2 3 However, the proportion of pre-
zygotic versus early postzygotic mutations within
the de novo mutation rate is not yet known.
In an attempt to further elucidate the origins of
de novo mutations, we performed deep whole-
genome sequencing of a healthy monozygotic twin
pair and their parents (figure 1A). Our working
hypothesis is that those de novo mutations
observed in only one twin would be of mitotic
origin, occur early during development possibly in
the post-twinning embryo and be detectable in
whole-blood-derived constitutive DNA (figure 1B).
We indeed observed, following a conservative char-
acterisation and validation, 23 shared, 8 twin
I-specific and 1 twin II-specific de novo SNVs
(table 1). These results implicate that a substantial
proportion of de novo SNVs in the genome of an
individual could be of early postzygotic origin.
STUDY SAMPLES AND METHODS
Study samples
A quad family consisting of a male 25-year-old
healthy monozygotic twin pair and their parents
(59 and 49 years old) participated in this study.
They were recruited to the control group of a study
on movement disorders, which was approved by
the institutional review boards (IRB) at Bilkent,
Hacettepe, Başkent and Çukurova Universities
(decisions: BEK02, 28.08.2008; TBK08/4,
22.04.2008; KA07/47, 02.04.2007; and 21/3,
08.11.2005, respectively). Zygosity of the twin pair
was assessed by comparing the SNVs of each twin
(99.8% similar). A Mendelian disorder has not
been documented in the family. The participants
had no exposure to chemotherapeutics. Written
informed consent prepared according to the guide-
lines of the Ministry of Health in Turkey was
attained from all individuals prior to the initiation
of this study. Blood, buccal smear and urine
samples were obtained from all participants. DNA
isolation from whole blood of each individual was
done using NucleoSpin Blood (Macherey-Nagel)
kit, according to the manufacturer’s protocol.
Buccal smear and urine cell-derived DNA were iso-
lated using DNeasy Tissue Kit (QIAGEN).
Whole-genome sequencing
Whole-genome sequencing data were generated
from blood DNA using Illumina HiSeq 2000
instrument. DNA samples were prepared for
whole-genome sequencing using Illumina TruSeq
DNA sample preparation kit according to the man-
ufacturer’s recommended protocols. For each of
the parent single library and for each of the twins
two libraries were prepared. For library prepar-
ation, 1–3 μg of genomic DNA was fragmented
through sonication. The resulting DNA fragments
were end-repaired and adapter ligation was done.
End-repaired and adapter-ligated DNA fragments
were run on 2% agarose gel for size selection.
Following the isolation of the fragments of
approximately 400 bp in size from the gel using
QIAGEN MinElute Gel Extraction Kit, size-
selected libraries were subjected to PCR amplifica-
tion. Enriched libraries were purified and their
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Figure 1 Discovery and characterisation of de novo single-nucleotide variations (SNVs) in a monozygotic twin pair. (A) Pedigree of the
whole-genome sequenced quad family. (B) Prezygotic versus postzygotic de novo SNVs found in twins I and II. (C) Annotation of the putative de
novo SNVs against human database GRCh37.68 using SnpEff,13 twin I and twin II: de novo SNVs shared between the twin pair. Twin I, twin II: twin
I-specific and twin II-specific de novo SNVs, respectively. The number of validated SNVs is shown above each bar. The only validated exonic SNV
shared by the twins is a synonymous mutation in PRSS58. (D) Sanger sequencing chromatogram for a twin I-specific intronic de novo SNV (XPO1
gene, chr2: 61728351, A>T).
Table 1 De novo mutations of the twin pair and the mutation rate estimation
All SNVs* Novel SNVs† De novo SNVs‡ Validated de novo SNVs§ Mutation rate (×10−8)¶
Sample dbSNP137 Novel Inherited De novo** Group I†† Group II‡‡ Total Group I Group II Total Group I Group II Total
Twin I 3 446 849 49 800 48 405 1396 159 83 242 23 8 31 0.97 0.34 1.31
Twin II 3 443 828 49 182 47 810 1372 48 207 1 24 0.04 1.01
*Number of all SNVs based on the variants calling through GATK.
†Number of SNVs that are not reported dbSNP137.
‡Number of de novo SNVs after applying filters (see online supplementary tables S5–S7).
§De novo SNVs validated through Sanger sequencing.
¶Mutation rate calculated based on the validated de novo SNVs and callable bases of each twin.
**Number of novel SNVs detected as de novo before applying filters (see online supplementary tables S5–S7).
††De novo SNVs classified as occurred in parental gametes or before separation of the zygote into two embryos.
‡‡De novo SNVs classified as occurred after separation of the zygote into two embryos but very early during development.
GATK, Genome Analysis Toolkit; SNV, single-nucleotide variation.
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quality was controlled with respect to the recommendations
provided by Illumina. Resulting libraries were sequenced on
eight lanes for each twin and four lanes for each parent using an
Illumina Hiseq 2000 instrument, employing 2×101–104 cycles
of incorporation. Imaging was performed using Illumina SBS
kits TruSeq V.3. Image analysis and base calling were done using
Illumina’s Real Time Analysis software V.1.13 with default
parameters.
Analysis of the whole-genome sequencing data
We converted base calling data into FASTQ files by using
Illumina’s CASAVA V.1.8.2 software package. The paired-end
reads were aligned to the NCBI Build 37 version (GRCh37) of
the human reference genome using Burrows-Wheeler Aligner
(BWA)4 V.0.6.1 with standard parameters. BAM files were gener-
ated from the resulting alignment files and merged into a single
BAM file using SAMtools5 V.0.1.18. We also used SAMtools to
mark and remove the PCR duplicates found in the resulting
BAM file. SNVs and insertions and/or deletions (indels) were
discovered using Genome Analysis Toolkit (GATK)6 software
V.1.6–13 with standard filtering parameters. In order to minim-
ise spurious SNV calls due to misalignment of bases in regions
around indels, the reads were locally realigned using
RealignerTargetCreator and IndelRealigner tools of GATK.
UnifiedGenotyper tool of GATK was used to generate an initial
list of raw variants. Finally, variant recalibration with the variant
quality score recalibration was applied to the SNVs/indels in
order to generate the final list of variants of four individuals in
a single VCF file. GATK-recommended hard filtering for very
low quality call-sets was applied with ‘AB <0.2||MQ0 >50||SB
>−0.10||QUAL <10’ parameters.
Discovery of the putative de novo SNVs shared by the twins
(group I)
We used the following approaches to discover putative de novo
SNVs and to classify them according to the timing of mutagen-
esis. We selectively extracted SNVs (both novel and reported in
dbSNP137) using GATK’s ‘SelectVariants’ module. We compared
the genotypes of the parents and the twin pair for each of the
SNVs concurrently using SnpSift7 V.1.1.3. We evaluated all pos-
sible genotype combinations, including those that could be classi-
fied as genotyping errors (such as those SNVs in a homozygous
state in one of the twins yet not present in one of the parents).
Using BEDtools,8 we first filtered the SNVs reported in SNP data-
base dbSNP137. Novel putative de novo SNVs were removed
when they were in non-variant sites or in sites for which the read
depth is less than 3 in each individual simultaneously. We filtered
the variants intersecting segmental duplications and/or simple
repeats in the genome using the intersectBed tool within the
BEDtools8 suite. Finally, we excluded de novo SNV candidates
classified as genotyping errors. Remaining de novo SNV candi-
dates were selected for further analysis. We considered the timing
of mutagenesis for the shared de novo SNVs as parental or post-
zygotic yet prior to twining.
Discovery of twin-specific putative de novo SNVs (group II)
This class of de novo SNVs was discovered using the above-
mentioned strategy including the comparison of the genotypes
of the mother, father and the twin pair for all SNVs simultan-
eously. SNVs observed in one of the twins and not observed in
the other twin as well as both parents were considered as candi-
date de novo SNVs. Same set of filters described above was
applied to the resulting candidate de novo SNVs to generate a
list of high-confidence putative twin-specific de novo SNVs. We
considered the timing of mutagenesis for the twin-specific de
novo SNVs as early postzygotic after the twinning event.
Evaluation of the putative de novo SNVs based on visual
examination
We used Integrative Genomics Viewer (IGV)9 to examine the
Sequence Alignment/Map (BAM) files to further evaluate the
putative de novo SNVs. We classified the variants in our initial
call-set as (a) inherited, (b) no variant, (c) located on a low-
quality read and (d) de novo. In the presence of more than
three reads supporting the variant in one or both parents, the
variant was classified as inherited and filtered. When the SNVor
indel density was high around the region flanking 40 bp the
putative de novo SNVs, we classified the sequencing reads sup-
porting the variants as ‘low-quality reads’ and filtered them.
Additionally, the putative de novo SNVs that are not supported
by at least three reads and located on the ‘low-quality reads’
were classified as ‘no variant’, and thus filtered. We included the
remaining putative de novo SNVs in our final call-set and
selected them for validation by Sanger-based capillary sequen-
cing (see online supplementary table S1).
Validation of de novo SNVs with Sanger sequencing
We selected all 120 high-confidence putative de novo SNVs for
validation. Of these, 37 could not be tested due to unavailability
of appropriate primers or PCR products of sufficient quality for
capillary sequencing. We designed primer pairs using Primer310
and PerlPrimer11 (see online supplementary table S2). PCR was
performed using 25 ng genomic DNA, One Taq DNA
Polymerase (New England Biolabs), 25 mM dNTPs (Fermentas),
5X One Taq standard reaction buffer and 10 pmol of each
forward and reverse primers. Thermocycling conditions were as
recommended by the manufacturer (94C° for 30 s; 30–35 cycles
of 94C° for 30 s, 58–60°C for 40 s and 68C° for 40 s; and 68C°
for 5 min). PCR products were analysed through 0.8% agarose
gel electrophoresis. Following the purification of PCR products,
Sanger sequencing was performed using forward primer, reverse
primer or both. CLC Main Workbench software package
(CLCBio Inc) was used to analyse Sanger sequencing data.
Calculation of the reference allele frequency
We used reference allele frequency (RAF) to evaluate the puta-
tive de novo SNVs. RAF is the total number of reads supporting
the reference allele as a fraction of total number of reads sup-
porting both reference and alternative allele.12 For the putative
de novo SNVs that are present in a heterozygous state, RAF
threshold was determined as 0.5–0.7 for the twins and 0.95–1.0
for the parents.
RESULTS
Mapping of the whole-genome sequencing data and
discovery of the sequence variants
We sequenced the whole genomes of the monozygotic twin pair
and their parents using the Illumina HiSeq2000 platform and
generated a total of 538 Gb genomic sequence with a mean
coverage depth of more than 30-fold per individual (see online
supplementary table S3). Using BWA,4 we mapped the
paired-end sequencing reads to the human reference genome
(GRCh37) and discovered genomic variants using the GATK.6
Herein, we discovered genomic variants using the multisam-
ple calling options of UnifiedGenotyper (a total of 170-fold
coverage). We identified approximately 3.4 million SNVs and
750 000 small insertions and deletions (indels) per genome (see
online supplementary table S4).
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Identification of the putative de novo SNVs
Examination of the genotypes of the twin pair and their parents
synchronously for each of the SNVs identified an initial set of
putative de novo SNVs. To distinguish true de novo SNVs from
sequencing and variant calling artefacts, we progressively
applied the following set of filters: (a) novelty vis-á-vis
dbSNP137, (b) having a coverage depth of at least three for the
site encompassing the variant in each individual, (c) presence
outside of the segmental duplications and/or repetitive DNA
and (d) genotyping error (see ‘Methods’). With this filtering
strategy, we identified a total of 290 high-confidence putative de
novo SNVs. Of these, 159 were shared by the twin pair (group
I); and 83 were specific for twin I and 48 for twin II (group II)
(see online supplementary tables S5–S7).
Selection of the high-confidence putative de novo SNVs for
validation
Subsequent to the identification of the initial call-set, we visually
examined the BAM files for all of the 290 high-confidence puta-
tive de novo SNVs using IGV.9 We also considered the allelic
depth for each SNV in each individual. This resulted in the fil-
tering of 86/159 shared, 54/83 twin I-specific and 30/48 twin
II-specific de novo SNVs (see ‘Methods’ and online
supplementary figure S1 and tables S8–S11).
We selected the remaining de novo SNV candidates for
Sanger sequencing (73 shared, 29 twin I-specific and 18 twin
II-specific) and also classified them by genomic context, which
revealed a biased distribution towards non-coding regions of the
genome (figure 1C).13 This is expected because of two reasons:
(a) non-coding regions constitute most of the genome, and (b)
they are subjected to less stringent evolutionary pressure.
We calculated the average RAF and coverage depth values for
all of the putative de novo SNVs (a) shared by the twin pair, (b)
specific to twin I and (c) specific to twin II (see ‘Methods’ and
online supplementary table S12). As expected, average RAF is
between 0.95 and 0.97 for the parents. For the twin pair,
average RAF for shared de novo SNVs is 0.59 for twin I and
0.55 for twin II, supporting the heterozygous presence of the
variants. And for the twin-specific de novo SNV candidates,
RAF values are consistent with mosaic presence (0.68–0.69) in
the twin that carries the variant.
Experimental validation of de novo SNV candidates
Of the 73 shared de novo SNV candidates, 49 could be tested
using capillary sequencing, and 23 confirmed to be de novo
SNV in heterozygous state (see online supplementary table S8).
We considered the timing of mutagenesis as parental or pre-
twinning zygote for these 23 shared de novo SNVs.
Of the 29 twin I-specific and 18 twin II-specific high-
confidence putative de novo SNVs (group II), 19 and 15,
respectively, could be analysed by capillary sequencing; and 8/
19 for twin I and 1/15 for twin II were confirmed (see online
supplementary tables S9 and S10).
In order to control the validity of the filtering process that
targeted the putative de novo SNVs classified as genotyping
error, we selected all 34 for capillary sequencing. Of these, 19
could be tested, and none confirmed as a de novo SNV (see
online supplementary table S13).
We confirmed the exclusive representation of twin-specific de
novo SNVs by simultaneous Sanger sequencing of the whole
family. The mutant allele for these twin-specific de novo SNVs
was clearly visible along with the wild-type allele in the capillary
chromatograms (figure 1D).
We calculated one more time the average RAF and coverage
depth values for the confirmed de novo SNVs as described
above (see online supplementary table S14). Average RAF is
0.96–1.00 for the parents. For the twin pair, it is 0.53 (twin I)
and 0.46 (twin II) for the shared; and 0.65 (twin I) and 0.78
(twin II) for the twin-specific de novo SNVs. These results are
consistent with the Sanger sequencing chromatograms, which
indicate the mosaic presence of twin-specific de novo SNVs.
Mosaic representation of a mutation in a parent could be inter-
preted as a de novo mutation in the twins.14–16 We therefore
extended our de novo mutation validation in blood (mesoderm)
to the analysis of DNA samples isolated from the buccal (ecto-
derm) and the urine (endoderm) cells of the parents. We did not
observe the de novo SNVs in either cell type, which suggests that
parental mosaicism does not contribute to the shared de novo
SNVs in the twins (see online supplementary figure S2).
Calculation of the mutation rate
Mutation rate was calculated based on the number of validated
de novo SNVs and callable bases. Bases with a minimum read
depth of 3 and do not intersect segmental duplications were
considered as callable. We calculated 2 703 445 479 bases for
twin I and 2 702 251 568 bases for twin II. We used the
formula below to calculate the mutation rates3:
m ¼ ðN(1þFNR)=L
At this point, N represents the number of de novo SNVs validated
by capillary sequencing, FNR is the false-negative rate (see online
supplementary table S15) and L is the total number of callable bases.
We calculated a rate of 0.97×10−8 bp per generation for de
novo SNVs shared by the twin pair. For twin-specific de novo
SNVs, we calculated the rate of 0.34×10−8 bp per generation for
twin I and 0.04×10−8 bp per generation for twin II, respectively.
DISCUSSION
The rate of de novo SNVs in healthy individuals has been inves-
tigated through whole-genome sequencing of mother–father–
offspring trios and yielded rates ranging between 0.82–
1.70×10–8 per base pair.17 Among these overall rates, the early
postzygotic de novo SNVs have not been distinguished from
those which have parental origin. Here we present overall de
novo SNV rate of 1.01 and 1.31×10–8 in a healthy monozy-
gotic twin pair consistent with previous direct estimations. We
also observe that parental mosaicism does not contribute to the
shared de novo SNVs in the twins. Furthermore, we report the
contribution of early postzygotic mutations to the average de
novo SNV burden with a rate of 0.04–0.34×10–8. Our deep
whole-genome sequencing-based approach combined with
effective filtering and validation enabled the direct measurement
of early postzygotic versus prezygotic de novo SNV rate.
The very first studies concerned with the estimation of somatic
mutation rate were restricted to coding or non-coding regulatory
regions and mainly focused on disease phenotypes.18 19 The
average somatic mutation rate has been reported to be
7.7×10−10.20 A more recent study that surveyed the whole
genome estimated the somatic mutation rate for common SNPs in
healthy monozygotic twins to be 1.2×10−7 per base pair.12 Conrad
and his colleagues distinguished the germline and non-germline
(somatic and cell line derived) mutations through whole-genome
sequencing of a CEU trio and provided a rate of 2.52×10−7 per
nucleotide for non-germline mutations. This estimate, which is
greater than the estimate presented in this study, is probably influ-
enced by mutagenicity and age of the cell culture.21
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De novo mutations that are not shared by monozygotic twins
could be cell line derived.22 We excluded this possibility by dir-
ectly sequencing whole-blood-derived DNA. We, however, point
out that the rate of postzygotic mutations is likely to be underes-
timated. This is because mutations that occur later in embryo
development will be observed as very low-frequency mosaic
SNVs that will be regarded as sequencing errors by mapping
and variant calling algorithms.23
High levels of allelic, locus and phenotypic heterogeneity
have important implications for gene discovery in complex
human diseases.24 Genomic microarrays and next-generation
sequencing technologies are now enabling researchers to dissect
the molecular basis of complex phenotypes that arise from de
novo mutations.25 This has been demonstrated in common neu-
rodevelopmental diseases such as schizophrenia26 and autistic-
spectrum disorders,27 pointing to a monogenic basis of disease
with the mutation representing a single event of large effect.
However, even after the spectacular success of these modern
genetic studies, a majority of cases remain unsolved. An added
level of complexity, consistent with this ‘de novo model’, could
be the timing of mutational events whereby early postzygotic de
novo mutations could be critically important. This is supported
by the observations that somatic mosaicism has been well docu-
mented in Mendelian phenotypes,14 28 29 including monozy-
gotic twins discordant for a given disorder,30 and by
demonstration of extensive genetic variation in human tissues31
including brain.32 It will be crucial to expand genome sequen-
cing studies to the next level of tissue or even cell type-specific
interrogation to better delineate causal mutations especially in
sporadic forms of Mendelian disorders.
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